Emmett T. Cunningham, Jr., MD, PhD, MPH
Dr. Cunningham joined Clarus with more than 20 years experience in the biomedical and biopharmaceutical sectors. Prior to Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc, where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology.
Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 250 publications. He is an Adjunct Clinical Professor of Ophthalmology at Stanford University, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University, a PhD in neuroscience from the University of California at San Diego for work done at The Salk Institute, and completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF.
Dr. Cunningham founded and is the Chairman of the Ophthalmology Innovation Summit (OIS).
Dr. Cunningham represents Clarus on the Board of Directors of Restoration Robotics, and is a Board Observer for Aerie, Ophthotech, and Pearl. Previous Directorshiups include SARcode Biosciences (acquired by Shire) and Neomend (acquired by Bard).